CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Price, Quote, News and Overview

What is the stock price of CAN FITE BIOPHARMA LTD-ADR today?

The current stock price of CANF is 1.81 USD. The price decreased by -5.24% in the last trading session.

What is the ticker symbol for CAN FITE BIOPHARMA LTD-ADR stock?

The exchange symbol of CAN FITE BIOPHARMA LTD-ADR is CANF and it is listed on the NYSE Arca exchange.

On which exchange is CANF stock listed?

CANF stock is listed on the NYSE Arca exchange.

What is the price forecast or stock price prediction for CAN FITE BIOPHARMA LTD-ADR stock?

8 analysts have analysed CANF and the average price target is 7.58 USD. This implies a price increase of 318.63% is expected in the next year compared to the current price of 1.81. Check the CAN FITE BIOPHARMA LTD-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.

What is CAN FITE BIOPHARMA LTD-ADR worth?

CAN FITE BIOPHARMA LTD-ADR (CANF) has a market capitalization of 9.03M USD. This makes CANF a Nano Cap stock.

How many employees does CAN FITE BIOPHARMA LTD-ADR have?

CAN FITE BIOPHARMA LTD-ADR (CANF) currently has 5 employees.

What are the support and resistance levels for CAN FITE BIOPHARMA LTD-ADR (CANF) stock?

CAN FITE BIOPHARMA LTD-ADR (CANF) has a support level at 1.56 and a resistance level at 1.82. Check the full technical report for a detailed analysis of CANF support and resistance levels.

Is CAN FITE BIOPHARMA LTD-ADR (CANF) expected to grow?

The Revenue of CAN FITE BIOPHARMA LTD-ADR (CANF) is expected to grow by 36.48% in the next year. Check the estimates tab for more information on the CANF EPS, Sales, EBIT and EBITDA future analyst estimates.

Should I buy CAN FITE BIOPHARMA LTD-ADR (CANF) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:

• The Technical Analysis (TA) tab contains a technical analysis of CANF, looking at technical quality and support and resistance levels
• The Fundamental Analysis (FA) tab contains a fundamental analysis of CANF, evaluating the profitability, health, valuation and growth aspects
• CAN FITE BIOPHARMA LTD-ADR (CANF) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
• CAN FITE BIOPHARMA LTD-ADR (CANF) Sales and EPS estimates to see what analysts future expectations are.
• CAN FITE BIOPHARMA LTD-ADR (CANF) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
• CAN FITE BIOPHARMA LTD-ADR (CANF) Insider and Institutional Ownership to learn about the owners and their transactions.
• CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Chart to make your own analysis
• CAN FITE BIOPHARMA LTD-ADR (CANF) Latest news and press-releases to stay up to date.

Does CAN FITE BIOPHARMA LTD-ADR (CANF) stock pay dividends?

CANF does not pay a dividend.

When does CAN FITE BIOPHARMA LTD-ADR (CANF) report earnings?

CAN FITE BIOPHARMA LTD-ADR (CANF) will report earnings on 2025-03-26, before the market open.

What is the Price/Earnings (PE) ratio of CAN FITE BIOPHARMA LTD-ADR (CANF)?

CAN FITE BIOPHARMA LTD-ADR (CANF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.18).

What is the Short Interest ratio of CAN FITE BIOPHARMA LTD-ADR (CANF) stock?

The outstanding short interest for CAN FITE BIOPHARMA LTD-ADR (CANF) is 4.66% of its float. Check the ownership tab for more information on the CANF short interest.

ChartMill assigns a fundamental rating of 2 / 10 to CANF. CANF scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.

Over the last trailing twelve months CANF reported a non-GAAP Earnings per Share(EPS) of -2.18. The EPS increased by 52.13% compared to the year before.

ChartMill assigns a Buy % Consensus number of 83% to CANF. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of -1.01% and a revenue growth 36.48% for CANF